Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sulfonylurea receptor 1 (SUR1) is a regulatory subunit of ATP-sensitive potassium (K_ATP) channels and certain non-selective cation channels. It is a member of the ATP-binding cassette (ABC) transporter family, encoded by the *ABCC8* gene. SUR1 plays a critical role in linking cellular metabolic state to membrane excitability, particularly in pancreatic beta cells and the central nervous system. It is the molecular target for sulfonylurea class antidiabetic drugs.
Sulfonylureas bind to SUR1, inhibiting K_ATP channel activity and leading to membrane depolarization and increased insulin secretion in pancreatic beta cells. In the CNS, SUR1 blockade can prevent brain swelling and enhance neuroprotection following injury.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sulfonylurea Receptor 1 (SUR1).